Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.93
ALKS's Cash to Debt is ranked higher than
56% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ALKS: 0.93 )
ALKS' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.93

Equity to Asset 0.67
ALKS's Equity to Asset is ranked higher than
73% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALKS: 0.67 )
ALKS' s 10-Year Equity to Asset Range
Min: -0.15   Max: 0.9
Current: 0.67

-0.15
0.9
Interest Coverage 1.67
ALKS's Interest Coverage is ranked lower than
54% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALKS: 1.67 )
ALKS' s 10-Year Interest Coverage Range
Min: 0.62   Max: 9.81
Current: 1.67

0.62
9.81
F-Score: 8
Z-Score: 8.00
M-Score: -2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 14.21
ALKS's Operating margin (%) is ranked higher than
89% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ALKS: 14.21 )
ALKS' s 10-Year Operating margin (%) Range
Min: -331.3   Max: 41.29
Current: 14.21

-331.3
41.29
Net-margin (%) 4.34
ALKS's Net-margin (%) is ranked higher than
83% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ALKS: 4.34 )
ALKS' s 10-Year Net-margin (%) Range
Min: -296.89   Max: 69.37
Current: 4.34

-296.89
69.37
ROE (%) 2.62
ALKS's ROE (%) is ranked higher than
82% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ALKS: 2.62 )
ALKS' s 10-Year ROE (%) Range
Min: -1828.02   Max: 54.69
Current: 2.62

-1828.02
54.69
ROA (%) 1.70
ALKS's ROA (%) is ranked higher than
84% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ALKS: 1.70 )
ALKS' s 10-Year ROA (%) Range
Min: -41.81   Max: 25.44
Current: 1.7

-41.81
25.44
ROC (Joel Greenblatt) (%) 20.63
ALKS's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. ALKS: 20.63 )
ALKS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -231.02   Max: 116.82
Current: 20.63

-231.02
116.82
Revenue Growth (%) 30.70
ALKS's Revenue Growth (%) is ranked higher than
93% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. ALKS: 30.70 )
ALKS' s 10-Year Revenue Growth (%) Range
Min: -22   Max: 69.1
Current: 30.7

-22
69.1
» ALKS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ALKS Guru Trades in Q1 2013

Jim Simons 117,800 sh (+163.03%)
Vanguard Health Care Fund 1,233,024 sh (+47.24%)
Jeff Auxier 54,551 sh (+0.74%)
Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones 11,900 sh (-5.56%)
Pioneer Investments 511,849 sh (-18.95%)
Steven Cohen 13,214 sh (-92.68%)
» More
Q2 2013

ALKS Guru Trades in Q2 2013

Joel Greenblatt 26,624 sh (New)
Steven Cohen 96,440 sh (+629.83%)
Jim Simons 794,686 sh (+574.61%)
Vanguard Health Care Fund 2,269,902 sh (+84.09%)
Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones Sold Out
Jeff Auxier 48,751 sh (-10.63%)
Pioneer Investments 209,249 sh (-59.12%)
» More
Q3 2013

ALKS Guru Trades in Q3 2013

Steven Cohen 128,699 sh (+33.45%)
Vanguard Health Care Fund 2,864,896 sh (+26.21%)
Murray Stahl 25,000 sh (unchged)
Joel Greenblatt Sold Out
Pioneer Investments 175,180 sh (-16.28%)
Jim Simons 661,686 sh (-16.74%)
Jeff Auxier 37,951 sh (-22.15%)
» More
Q4 2013

ALKS Guru Trades in Q4 2013

Vanguard Health Care Fund 3,672,087 sh (+28.18%)
Pioneer Investments 213,043 sh (+21.61%)
Murray Stahl 25,000 sh (unchged)
Steven Cohen Sold Out
Jeff Auxier 31,851 sh (-16.07%)
Jim Simons 505,586 sh (-23.59%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-12-31 Add 28.18%0.1%$30.17 - $41.12 $ 44.1220%3672087
Vanguard Health Care Fund 2013-09-30 Add 26.21%0.07%$28.66 - $35.35 $ 44.1235%2864896
Joel Greenblatt 2013-09-30 Sold Out 0.03%$28.66 - $35.35 $ 44.1235%0
Vanguard Health Care Fund 2013-06-30 Add 84.09%0.11%$22.35 - $33.72 $ 44.1251%2269902
Joel Greenblatt 2013-06-30 New Buy0.03%$22.35 - $33.72 $ 44.1251%26624
Vanguard Health Care Fund 2013-03-31 Add 47.24%0.04%$18.52 - $23.81 $ 44.12102%1233024
John Burbank 2012-03-31 Sold Out 0.23%$16.14 - $19.5 $ 44.12168%0
Vanguard Health Care Fund 2012-03-31 New Buy0.07%$16.14 - $19.5 $ 44.12168%787900
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 342.80
ALKS's P/E(ttm) is ranked lower than
71% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. ALKS: 342.80 )
ALKS' s 10-Year P/E(ttm) Range
Min: 3.59   Max: 1430
Current: 342.8

3.59
1430
P/B 6.00
ALKS's P/B is ranked higher than
52% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ALKS: 6.00 )
ALKS' s 10-Year P/B Range
Min: 1.66   Max: 379.8
Current: 6

1.66
379.8
P/S 10.80
ALKS's P/S is ranked higher than
53% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. ALKS: 10.80 )
ALKS' s 10-Year P/S Range
Min: 2.19   Max: 35.3
Current: 10.8

2.19
35.3
PFCF 54.10
ALKS's PFCF is ranked lower than
57% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. ALKS: 54.10 )
ALKS' s 10-Year PFCF Range
Min: 10.27   Max: 167.27
Current: 54.1

10.27
167.27
EV-to-EBIT 125.00
ALKS's EV-to-EBIT is ranked lower than
78% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ALKS: 125.00 )
ALKS' s 10-Year EV-to-EBIT Range
Min: 3.6   Max: 628
Current: 125

3.6
628
Shiller P/E 198.90
ALKS's Shiller P/E is ranked lower than
66% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.60 vs. ALKS: 198.90 )
ALKS' s 10-Year Shiller P/E Range
Min: 28.68   Max: 394.67
Current: 198.9

28.68
394.67

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 16.10
ALKS's Price/Tangible Book is ranked lower than
76% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ALKS: 16.10 )
ALKS' s 10-Year Price/Tangible Book Range
Min: 1.25   Max: 336
Current: 16.1

1.25
336
Price/DCF (Projected) 5.45
ALKS's Price/DCF (Projected) is ranked lower than
59% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. ALKS: 5.45 )
ALKS' s 10-Year Price/DCF (Projected) Range
Min: 2   Max: 20.95
Current: 5.45

2
20.95
Price/Median PS Value 1.50
ALKS's Price/Median PS Value is ranked higher than
52% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALKS: 1.50 )
ALKS' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 14.23
Current: 1.5

0.38
14.23
Price/Graham Number 15.16
ALKS's Price/Graham Number is ranked lower than
83% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. ALKS: 15.16 )
ALKS' s 10-Year Price/Graham Number Range
Min: 0.9   Max: 38.02
Current: 15.16

0.9
38.02
Earnings Yield (Greenblatt) 0.80
ALKS's Earnings Yield (Greenblatt) is ranked lower than
68% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ALKS: 0.80 )
ALKS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 27.9
Current: 0.8

0.2
27.9
Forward Rate of Return (Yacktman) 0.07
ALKS's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ALKS: 0.07 )
ALKS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.1   Max: 2.2
Current: 0.07

-6.1
2.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8AK.Germany
Alkermes PLC is a biotechnology company. It is engaged in developing, manufacturing and commercializing medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious diseases. It has a diversified portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders such as addiction, schizophrenia and depression. The Company relies solely on its manufacturing facility in Wilmington, Ohio for the manufacture of RISPERDAL CONSTA, VIVITROL, polymer for BYDUREON and some of our product candidates.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide